1. Pink Sheet
  2. >>Biosimilars & Generics

Teva Fined Half A Billion Dollars Over European Copaxone Antitrust Breach

Firm Says Decision Is ‘Not Supported By Facts’ And Vows Appeal

 
• By Dave Wallace

Teva has been fined €463m – just over half a billion US dollars – over a breach of EU antitrust rules, after the European Commission found that it abused its dominant position to delay competition to Copaxone, including by misusing the patent system and disparaging rivals. The firm has strongly disagreed with the decision – which is claims is “legally untested” and “not supported by the facts” – and says it will appeal.

The European Commission provided an explanatory infographic (European Commission)

Teva has been fined €462.6m ($503m) by the European Commission for abusing its dominant position “to delay competition to its blockbuster medicine for the treatment of multiple sclerosis, Copaxone (glatiramer acetate).”

The commission said Teva had been sanctioned for “misuse of the patent system and disparagement” to delay competition to the once-flagship brand, finding that Teva “artificially extended the patent protection...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars & Generics

More from Italy